| Name | CDDO-dhTFEA |
| Description | CDDO-dhTFEA, a synthetic oleanane triterpenoid, effectively activates Nrf2 while inhibiting the NF-κB pro-inflammatory transcription factor. It restores mean arterial pressure (MAP), elevates Nrf2 levels and the expression of related genes, attenuates NF-κB and transforming growth factor-β pathway activation, and mitigates glomerulosclerosis, interstitial fibrosis, and inflammation in rats with chronic kidney disease (CKD). |
| In vivo | CDDO-dhTFEA restores hypertension, increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis, and inflammation in the chronic kidney disease rats [2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (5.74 mM), Sonication is recommended. DMSO : 250 mg/mL (434.99 mM), Sonication is recommended.
|
| Keywords | RTA dh-404 | RTA dh404 | RTA dh 404 | Nuclear factor-κB | Nuclear factor-kappaB | Nrf2 | NF-κB | NFκB | NF-kB | NFkB | Keap1-Nrf2 | Inhibitor | inhibit | CDDO-dhTFEA | CDDOdhTFEA | CDDO dhTFEA |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Ethyl linoleate | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Ovarian Cancer Compound Library | Antioxidant Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Bioactive Lipid Compound Library | Preclinical Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library | Anti-Hypertension Compound Library |